foxo4 dri senolytic peptide human trial 2024 2025 Computational design of targeting FOXO4. a, Domains of Peptide inhibitors targeting FOXO4-p53 interactions

A GHK-Cu subcutaneous injection, by contrast, introduces the same molecule into the systemic circulation, where its distribution, its interaction with copper-binding plasma proteins, and its ultimate fate are governed by whole-body copper physiology rather than by local skin diffusion

The set contains three peptides: BPC-157 (10 mg), TB-500 (10 mg) and GHK-Cu (50 mg), supplied lyophilised

Instead of investing heavily in custom research and large production volumes, founders can begin with a flexible private label structure that allows them to test their concept in the real market

Discreet Packaging Plain, unmarked packaging with no indication of contents